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Cystatins, cysteine peptidase inhibitors, as regulators 
of immune cell cytotoxicity
Abstract
Cystatins comprise a superfamily of evolutionarily related proteins, pres-
ent in all living organisms, from protozoa to mammals. They act as inhibi-
tors of cysteine peptidases although they can also function independently of 
their inhibitory function. Cysteine cathepsins are implicated in various 
physiological and pathological processes. In the immune response they are 
involved in antigen processing and presentation, the cytotoxicity of natural 
killer (NK) cells and cytotoxic T lymphocytes (CTL), migration and adhe-
sion of immune cells, cytokine and growth factor regulation and toll-like 
receptor signalling. Cystatins are probably involved in the regulation of all 
these processes; importantly, cystatin F has a crucial role in the regulation of 
immune cell cytotoxicity. NK cells and CTLs exploit the granzyme/perforin 
pathway for target cell killing, with perforin and granzymes as crucial ef-
fector molecules. Granzymes are synthesized as inactive pro-granzymes and 
need to be proteolytically activated by cathepsins C and H. Cystatin F is the 
main regulator of the activity of cathepsins C and H in cytotoxic cells and, 
consequently, regulates their cytotoxicity. The role of cystatins and cysteine 
cathepsins in the immune response is presented, with emphasis on their role 
in the regulation of cytotoxicity of NK cells and CTLs.
INTRODUCTION
Peptidases are proteolytic enzymes that cleave peptide bonds. They have been seen primarily as enzymes involved in food digestion and 
intracellular protein catabolism (1), although in past decades their im-
portant roles in diverse physiological and pathological processes, such 
as cell death and survival, wound healing, the immune response, viral, 
bacterial and parasite infections, cancer, osteoporosis, cardiovascular, 
neurodegenerative and inflammatory diseases have been established (2). 
Among those peptidases involved in immune processes, many studies 
have been focused on a group of endosomal/lysosomal cysteine pepti-
dases, the cysteine cathepsins, whose involvement in antigen processing 
and presentation, cytotoxicity of natural killer (NK) cells and cyto-
toxic T lymphocytes (CTL), migration and adhesion of immune cells, 
cytokine and growth factor regulation and toll like receptor (TLR) sig-
nalling have been demonstrated (3, 4). In addition to cathepsins, an-
other lysosomal cysteine peptidase, legumain or asparaginyl endopep-
tidase, has also been associated with the immune response, most notably 
with antigen presentation and TLR signalling (4, 5). The activities of 
cysteine cathepsins and legumain are regulated on different levels. Their 
expression, for example, is regulated at transcriptional or translational 
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CLIP  – class-II associated invariant chain peptide 
CTL  – cytotoxic T lymphocytes CD8+
IFN  – interferon 
Ii  – invariant chain 
IL  – interleukin 
LFA-1  – lymphocyte function-associated antigen 1 
LIP  – leupeptin-induced protein 
LPS  – lipopolysaccharide 
MACPF – membrane attack complex/perforin 
MHC  – major histocompatibility complex 
NK cells – natural killer cells 
SLIP  – small-leupeptin-induced protein 
TGF-b  – transforming growth factor b
TLR  – toll like receptor 
TNF-a  – tumour necrosis factor a
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site of action, and compartmentalised into lysosomes or 
other organelles. Their activity can be regulated by oxida-
tion of the active site cysteine or by endogenous protein 
inhibitors (6), the latter being presented in more detail.
CYSTEINE CATHEPSINS  
AND LEGUMAIN AS REGULATORS  
OF THE IMMUNE RESPONSE
In humans, cysteine cathepsins comprise a group of 11 
lysosomal peptidases (cathepsins B, C, F, H, K, L, O, S, 
V, X and W). They are members of the papain family, 
classified as clan CA (7). The expression pattern, levels, 
localization and specificities of cysteine cathepsins differ, 
contributing to their various physiological roles. Cathep-
sins B, H, L and C are expressed ubiquitously in cells and 
tissues, while expression of others is restricted to specific 
cell types. They are endopeptidases, with the exception of 
cathepsins B, C, H and X. Cathepsins B and X are car-
boxypeptidases, cleaving substrates at the C-terminal end, 
while cathepsins B and H are aminopeptidases, cleaving 
substrates at the N-terminal end. Interestingly, in addition 
to exopeptidase activity, cathepsins B and H also exhibit 
endopeptidase activity (7, 8). Cathepsin B can act as an 
endo- or exopeptidase due to the position of the struc-
tural element, termed the occluding loop, while in cathep-
sin H the type of activity is determined by a minichain, 
an octapeptide derived from the pro-peptide that is bound 
to the mature enzyme by a disulphide bond. In the ab-
sence of a minichain, cathepsin H acts mainly as an en-
dopeptidase (1). Cysteine cathepsins are predominantly 
localized within the endosomal/lysosomal pathway, how-
ever, they have been found also in the nucleus, the cytosol, 
on the cell membrane or secreted from the cells (9). They 
participate in numerous physiological processes, not only 
in terminal protein degradation in the endosomal/lyso-
somal pathway, but also in proteolytic activation of pro-
hormones. For example, in the thyroid, liberation of the 
thyroid hormone thyroxin from its pro-hormone thyro-
globulin is mediated by cysteine cathepsins (10). In addi-
tion, cysteine cathepsins activate other protein precursors 
and are thus important in several other cell processes in-
cluding antigen presentation and processing (6). Secreted 
cysteine cathepsins on the other hand are important in the 
remodelling of the extracellular matrix and, consequently, 
in wound healing, bone remodelling and tumour cell in-
vasion (6, 11). Furthermore, the activity of extralysosom-
al cathepsins can regulate apoptosis, a process crucial in 
homeostasis of immune and other cells (12). For instance, 
cathepsins B, H, K, L and S process the pro-apoptotic 
molecule Bid, while cathepsins B, H, L, K and S degrade 
anti-apoptotic molecules Bcl-2, Bcl-xL and Mcl-1, thereby 
triggering apoptosis (12–14).
Legumain is a member of C13 family of cysteine pep-
tidases. It has a broad tissue distribution, being most 
abundant in kidney and testis and in various types of 
antigen presenting cells. Inside the cells it is present in the 
endosomal/lysosomal pathway, where it acts as an endo-
peptidase. However, legumain is also found in the cyto-
sol, nucleus or extracellularly and, in addition to its endo-
peptidase activity, also acts as a carboxypeptidase and 
peptide ligase (5).
Cysteine cathepsins are involved in various aspects of 
innate and adaptive immune response. In the innate re-
sponse they were shown to regulate TLR signalling. The 
first cathepsin shown to be implicated in this process was 
cathepsin K. Its pharmacological or genetic inhibition 
leads to reduction in TLR9-induced signalling (15). Ca-
thepsins B, L, S and F can also regulate TLR9 function 
(16–18). Cathepsins cleave the ectodomain of TLR9 and, 
although the full-length and cleaved forms can both bind 
their ligands, only the cleaved form can recruit the signal-
ling adaptor MyD88 on activation (16, 17). The cleavage 
is a stepwise process where most of the ectodomain is first 
removed by legumain and cathepsins, followed by trim-
ming of the exposed N-terminal catalysed only by cathep-
sins (19). Nevertheless, in the absence of legumain cathep-
sins seem to be sufficient to carry out TLR processing. 
TLR 3 and 7 are processed in the same manner (19), sug-
gesting that proteolytic activation of TLR receptors may 
be a general regulatory strategy, important in preventing 
unwanted responses to self-nucleic acids (19).
Cathepsins are also involved in cytokine activation 
and/or inhibition. For example, interleukin-8 (IL-8) is 
activated by N-terminal truncation by cathepsin L in hu-
man fibroblasts (20) and optimal trafficking and process-
ing of tumour necrosis factor a (TNF-a) is dependent on 
cathepsin B activity (21). On the other hand, cytokines 
can regulate the activity of cathepsins like TNF-a and 
IL-1b that increase the activity of cathepsins S and B in 
dendritic cells, enhancing major histocompatibility com-
plex (MHC) class II dimer formation and T cell recogni-
tion (22).
Cathepsin X has been shown to modulate signal trans-
duction by interacting with integrin receptors. It can in-
teract independently of proteolysis, through direct bind-
ing of the RGD motif in pro-cathepsin X with integrins 
or via proteolysis, through cleavage of integrin receptors 
by active cathepsin X (23, 24). In macrophages and 
monocytes, cleavage of b2-integrin receptor Mac-1 
(CD11b/CD18) leads to increased phagocytosis, cell ad-
hesion and activation of T lymphocytes (25) while, in 
dendritic cells, this cleavage is required for their adhesion 
and maturation (26).
Cysteine peptidases are probably best known for their 
role in the activation and migration of T lymphocytes. In 
the latter, for example, cathepsin X modulates the activ-
ity of b2 integrin receptor lymphocyte function-associat-
ed antigen 1 (LFA-1), thus enhancing T lymphocyte mi-
gration and homotypic aggregation (27). Even more 
prominent is the involvement of cysteine cathepsins in 
activation of MHC class II-dependent T cells. In antigen 
presenting cells they participate in two main processes, 
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the first being the degradation of invariant chain (Ii), a 
chaperone that prevents premature loading of peptide to 
MHC class II molecules, while the second one is the deg-
radation of endocytosed antigens to antigenic peptides. 
The degradation of Ii is a stepwise process including, first, 
formation of the 22 kDa LIP (leupeptin-induced protein)-
fragment, followed by formation of the 10 kDa SLIP 
(small-leupeptin-induced protein)-fragment and finally 
CLIP (class-II associated invariant chain peptide)-frag-
ment (28). The rate-limiting step is the conversion of SLIP 
to CLIP, catalysed by cathepsin S in dendritic and B cells, 
by cathepsin V in thymic epithelial cells and by both en-
zymes in macrophages (29). In macrophages an addi-
tional peptidase, cathepsin F, can also catalyse the final Ii 
degradation step (30). The first steps of Ii processing in 
antigen presenting cells are less specific and involve mul-
tiple peptidases, among them legumain. However, it is 
not clear whether legumain cleaves Ii directly or is in-
volved in Ii processing indirectly, through activation of 
cathepsins (31–33). In addition to preventing premature 
peptide loading, Ii is also involved in the migration of 
dendritic cells. Accumulation of Ii inhibits dendritic cell 
migration while proteolytic degradation of Ii makes them 
migrate faster (34). The degradation of endocytosed pro-
teins into immunogenic peptides involves various cathep-
sins, as well as legumain. The difference in generation as 
well as distruction of immunogenic peptides may trigger 
specific MHC class II dependent T cell response (28).
Last, but not least, cathepsins are also important for 
the activation of granule-localized serine peptidases from 
their precursor forms, including cathepsin G, elastase and 
proteinase-3 in neutrophils, granzymes A and B in NK 
and T cells and chymase in mast cells (4). These serine 
peptidases are the main executors of the effector functions 
of these cells. However, there is considerable redundancy 
in the mechanism of activation of granule-localized serine 
peptidases in cytotoxic cells. The first peptidase discovered 
was cathepsin C, which removes two residues from the 
N-terminus (35). Accordingly, cathepsin C null mice were 
not able to activate neutrophil and mast cell granule pep-
tidases (36, 37) however, in cytotoxic T cells, granzyme 
B activity was reduced, but not absent (38). Likewise, in 
Papillon-Lefévre syndrome, a genetic disorder character-
ised by cathepsin C deficiency, severe gingivitis and skin 
infections are present, but not a general T-cell immuno-
deficiency (39). These results suggested that there are 
other peptidases involved in granzyme activation and, for 
granzyme B, cathepsin H was found as an additional pep-
tidase. However, cytotoxic lymphocytes from cathepsin 
C and H null mice still retain residual granzyme B activ-
ity, implying that further peptidases are involved in gran-
zyme B activation (40). In addition to activation of gran-
ule-localized serine peptidases, cathepsins are also involved 
in perforin processing in cytotoxic cells. Perforin, the 
pore-forming protein of cytotoxic granules, is cleaved by 
cathepsin L at the C-terminus. Again, other cathepsins 
are probably also involved in perforin activation (41).
CYSTATINS AND THE IMMUNE 
RESPONSE
Cystatins constitute a superfamily of evolutionarily 
related proteins, with representatives present in all living 
organisms, from protozoa to mammals. They act as in-
hibitors of cysteine peptidases from C1 family, but some 
members can inhibit the C13 family by a second active 
site (42). Based on their structure, human cystatins can 
be divided into three types. Type I cystatins, stefins A and 
B, are approximately 100 amino acid residues long, they 
are not glycosylated and do not contain disulphide bonds. 
They are found mainly intracellularly but can also be se-
creted. Type II cystatins, cystatins C, D, E/M, F, S, SA, 
SN, CRES, testatin, cystatins 11, 12, 13 and 14, have 
approximately 120 amino acid residues, contain two con-
served disulphide bridges and are mainly secreted to the 
extracellular space. The most complex are type III cys-
tatins, the kininogens, that contain three type II domains. 
They contain approximately 350 amino acid residues, 
have eight disulphide bonds and are glycosylated. They 
are secreted extracellularly and found intravascularly, 
where they provide systemic protection against leaking 
endolysosomal cysteine peptidases (43, 44).
Cystatins function mainly as reversible, tight-binding 
inhibitors of cysteine cathepsins, and are involved in sev-
eral immune processes controlling the cathepsins. In ad-
dition to inhibiting endogenous cysteine peptidases, they 
can also inhibit cysteine peptidases from microorganisms 
and parasites, helping in defence against microbial infec-
tions (44). Furthermore, cystatins can also act indepen-
dently from their inhibitory function; for example cys-
tatin C was shown to interact with transforming growth 
factor b (TGF-b) type II receptor, thus interfering with 
TGF-b binding (45).
Stefin A has a broad inhibitory profile, but shows selec-
tive expression in tissues involved in the first-line immune 
response like skin epithelial cells (46) and polymorpho-
nuclear granulocytes (47); it might be thus relevant for 
inhibiting peptidases from microbes invading through 
the skin. Furthermore, stefin A was proposed to have an 
important function in the development of the epidermis 
and in the associated neonatal immune response (48). It 
is also highly expressed in follicular dendritic cells of ger-
minal centres in secondary lymphoid organs, that select 
B cells during germinal centre reactions (49). In this pro-
cess stefin A is transported from follicular dendritic cells 
to B cells, where it could prevent apoptosis (50).
Stefin B, on the other hand, is present in most human 
cells (51). In the immune response its expression was 
shown to be upregulated in human monocytes after lipo-
polysaccharide (LPS) stimulation, implying its involve-
ment in the response to bacterial infections (52). In addi-
tion, in mouse peritoneal macrophages activated with 
interferon g (IFN-g), addition of stefin B enhanced nitric 
oxide production through a mechanism distinct from its 
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inhibitory activity (53). It was further demonstrated that 
stefin B deficiency in bone marrow-derived macrophages 
leads to decreased expression of IL-10 and increased secre-
tion of nitric oxide, consistent with a pro-inflammatory 
phenotype (54). Similarly, stefin B null mice, character-
ised by a phenotype similar to Unverricht-Lundborg dis-
ease, were significantly more sensitive to LPS-induced 
sepsis and contained larger amounts of pro-inflammatory 
cytokines IL-1b and IL-18 in the serum (55). In a recent 
study it was confirmed that stefin B deficiency in stefin B 
null mice leads to down-regulation of IFN regulated 
genes in microglia, the resident tissue macrophages in the 
central nervous system, providing a general mechanism 
for stefin B involvement in innate immune response (56).
Cystatin D is found in saliva and tears in humans (57), 
where it probably functions as an inhibitor of exogenous 
peptidases. Indeed, it has been found to be a potent in-
hibitor of coronavirus replication (58). In a recent study 
it was shown that, in rats, cystatin D is produced and 
secreted by parotid acinar cells, but also in antigen pre-
senting cells in parotid glands, even if the cystatin D gene 
was not expressed in these cells (59). This suggests that 
cystatin D, similarly to cystatin F as described below, can 
act in trans. Cystatin D localization in antigen presenting 
cells and its preferential inhibition of cathepsin S (60) 
suggest, that it could be involved in antigen presentation.
Cystatins S, SN and SA are non-glycosylated proteins 
found in saliva, tears, urine, seminal plasma, liver and 
muscle (61). Because of their glandular localization they 
probably also act as inhibitors of exogenous peptidases. 
Accordingly, they were found to be effective inhibitors 
against cysteine peptidases from parasites, for example 
cruzipain from Trypanosoma cruzi (62). Furthermore, 
they might play a role in protection against viral infec-
tions, as they can suppress the infectivity of herpes sim-
plex virus 1 (63) and were found up-regulated in children 
with seasonal influenza A infection (64). Similarly, cys-
tatin SN was up-regulated in patients with seasonal al-
lergic rhinitis (65) and may play a role in the inactivation 
of peptidase allergens. In addition to their role in inhibit-
ing exogenous peptidases, incubation of human CD4+ T 
cells with cystatin SA leads to increased IFN-g production 
(66) additionally confirming a role for salivary cystatins 
in the immune response.
Of the type II cystatins the most important role in the 
immune response is attributed to cystatins C and F. Cys-
tatin C is the most abundant human cystatin, expressed 
in all human tissues and cell types. Like most type II 
cystatins it is secreted and found at high levels in body 
fluids, where it most probably acts as an emergency in-
hibitor, neutralizing redundant proteolytic activity outside 
cells (44, 51). It has diagnostic and prognostic value in 
several diseases; for example it is a marker of glomerular 
filtration rate and thus of kidney function (51). Levels of 
serum cystatin C are associated with inflammation in 
systemic lupus erythematosus (67) In addition, it has been 
found to be a positive acute-phase reactant in chronic ob-
structive pulmonary disease (68). Furthermore, cystatin 
C expression and protein levels were found to be decreased 
following maturation of dendritic cells (69, 70). It has 
been suggested that cystatin C plays a role in antigen pre-
sentation by regulation of cathepsin S activity, however, 
studies on dendritic cells from cystatin C null mice 
showed that cystatin C is not involved in this process (71).
Cystatin F is expressed primarily in cells of the im-
mune system, such as dendritic cells, T cells and NK cells 
(72–74). While other type II cystatins are mainly secreted, 
the intracellular levels of cystatin F are unusually high, 
implying an important intracellular role (75). It is ex-
pressed as a disulphide linked dimer and targeted to the 
endosomal/lysosomal pathway through the mannose-6-
phosphate sorting machinery (76), where it can regulate 
the activity of cysteine peptidases. However, cystatin F is 
not active as an inhibitor of cysteine cathepsins until it is 
converted to the monomeric form (77). Dimer to mono-
mer conversion is facilitated by proteolytic cleavage at the 
N-terminus (78), probably by cathepsin V (41). Proteo-
lytic processing changes its inhibitory profile and, while 
full-length cystatin F inhibits legumain and cathepsins F, 
H, K, L, S and V (77), the N-terminal processing is es-
sential for cathepsin C inhibition (78). In addition, intra-
cellular localization of the dimeric and monomeric forms 
is different: the dimeric form is found primarily in endo-
plasmic reticulum and Golgi apparatus, while the mono-
meric form is found in lysosomes and is completely trun-
cated at the N-terminus (78). Furthermore, the secreted 
dimeric cystatin F can be internalized by other cells 
through the mannose-6-phosphate receptor pathway and 
can thus function also in trans (76). Levels and localiza-
tion of cystatin F depend on the physiological state of the 
cell. For example, cystatin F is strongly upregulated in 
LPS-stimulated monocyte derived dendritic cells (69) and 
downregulated by all-trans-retinoic acid in the U937 cell 
line differentiated towards the granulocytic pathway or 
by, phorbol ester, towards macrophages (75). Further-
more, cystatin F co-localizes with cathepsin S in imma-
ture dendritic cells, suggesting that it could reduce cathep-
sin S activity in the earlier steps of dendritic cell maturation 
(79). In the same study cystatin F was found co-localized 
with cathepsin L in maturing, adherent dendritic cells. 
Through regulation of cathepsin L activity, cystatin F 
could regulate pro-cathepsin X activity, which is involved 
in adhesion and maturation of dendritic cells as described 
above. Moreover, cystatin F has been shown to be an im-
portant survival factor for eosinophils (80). Eosinophils 
from cystatin F null mice had lower granularity and fast-
er turnover than those from wild-type mice. In a model 
of ovalbumin-specific allergic lung inflammation, the ac-
cumulation of eosinophils in the airways of cystatin F null 
mice was significantly lower than that in those of the wild-
type, while the incidence of early apoptotic eosinophils 
was higher, suggesting a role for cystatin F in eosinophil 
survival. Furthermore, cystatin F null mice infected with 
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nematode parasite Burgia malayi were unable to eliminate 
the infection, while wild-type mice successfully cleared 
the parasite. Abnormal granule biogenesis and the shorter 
lifespan of cystatin F null eosinophils is most probably a 
consequence of dysregulated activity of cysteine cathep-
sins that leads to disturbed processing of multiple granule 
constituents, such as major-basic protein-1. However, no 
one peptidase was found to be the target of cystatin F in 
eosinophils, and it is likely that cystatin F functions 
through regulation of multiple peptidases. (80). Cystatin 
F is also an important regulator of NK and T cell cyto-
toxicity – it regulates the activity of granzyme conver-
tases cathepsins C and H. This will be explained in more 
detail in the following sections.
CYTOTOXIC IMMUNE CELLS
Cytotoxic immune cells include CTLs and NK cells 
and constitute the major effector mechanism in the cel-
lular immune response against microbial infections and 
cancer cells (81). Even though the activation of CTLs dif-
fers from that of NK cells, the molecular mechanisms they 
employ for target cell killing are basically the same and 
include at least three distinct pathways. Two of these, i.e. 
the death receptor and granzyme/perforin pathways, em-
ploy direct cell-cell contact, while the third mechanism is 
mediated by secreted cytokines, e.g. IFN-g and TNF-a. 
The death receptor pathway involves binding of Fas, a 
ligand expressed on the surface of cytotoxic cells, to the 
Fas receptor on the target cell, after which apoptosis is 
triggered in a caspase-dependent manner. The granzyme/
perforin pathway involves exocytosis of cytotoxic granules 
containing perforin and granzymes into the intracellular 
space and subsequent diffusion of granzymes into the tar-
get cell. Once in the target cell, granzymes trigger caspase-
dependent or independent cell death (81–83). The death 
receptor pathway is exploited primarily for elimination of 
self-reactive lymphocytes (84), while the granzyme/per-
forin pathway is used by cytotoxic cells for elimination of 
virus-infected and transformed cells (81).
Perforin and granzymes are located in cytotoxic gran-
ules, also termed ‘secretory lysosomes’ (85). In addition to 
perforin and granzymes, the cytotoxic granules contain 
several other molecules, such as cysteine peptidases cathe-
psins C, H and L and lysosomal membrane proteins 
Lamp-1, Lamp-2 and Lamp-3 (40, 86).
Perforin is a cytotoxic, pore-forming protein, a typical 
member of membrane attack complex/perforin (MACPF) 
protein family. It consists of an N-terminal MACPF/cho-
lesterol dependent cytolysin domain with amphipathic 
helices for membrane protrusion, an epidermal growth 
factor domain with unknown function, and a C-terminal 
C2 domain responsible for calcium-dependent membrane 
binding (87). Perforin is synthesised as an inactive precur-
sor requiring proteolytic cleavage at the C-terminal for its 
activation (88). However, it was shown that perforin with 
intact C-terminal has unchanged activity, making the 
role of proteolytic cleavage unclear (89). Perforin is es-
sential for diffusion of granzymes into the target cell; 
perforin null mice completely lose their ability to kill tar-
get cells through the perforin/granzyme pathway and 
become susceptible to various immunogenic challenges, 
such as viral infection (90). In humans, defects in perforin 
synthesis, function or release lead to familial haemo-
phagocytic lymphohistiocytosis, a severe immunoregula-
tory disorder (90).
Granzymes are a family of structurally related neutral 
serine peptidases. In humans five different granzymes 
have been described, granzymes A, B, H, M and K, with 
different substrate specificities and expression (91, 92). 
Similarly to other serine peptidases, granzymes are acti-
vated by a two-step process. They are first targeted to the 
endoplasmic reticulum and Golgi apparatus, where the 
leader sequence is removed, whereas a dipeptide remains 
at the N-terminal (93). Inside cytotoxic granules this 
dipeptide is cleaved off and the granzymes are activated. 
Cleavage of the dipeptide is carried out primarily by 
cathepsin C however, at least for granzyme B, it can be 
catalysed also by cathepsin H (40, 94). The expression of 
granzymes is in generally limited to lymphoid cells and 
the only cells known to synthesize and store granzymes 
constitutively are NK cells, natural killer T cells (NKT), 
and gd T cells, whereas in other cells granzymes are ex-
pressed only after stimulation, e.g. antigen stimulation in 
CTLs (92). In addition, non-cytotoxic roles for granzymes 
have been proposed, such as direct cleavage of viral pro-
teins or activation of pro-inflammatory cytokines (83).
Even though they possess the same cytotoxic mecha-
nism, NK cells and CTLs differ in several other aspects. 
NK cells are one of key components of the innate immune 
response and are morphologically characterized as large 
granular lymphocytes and, phenotypically, as CD56+ 
CD3- cells. In the peripheral blood they constitute the 
third largest population of lymphocytes after T and B cells 
(95). Based on the expression of CD56, NK cells can be 
divided into two subsets, CD56dim and CD56bright. CD-
56dim NK cells form 90% of the NK cell population in 
the peripheral blood, express low affinity Fc receptor 
(CD16) and are considered to be the main mediators of 
the cytotoxic response. CD56bright on the other hand are 
immature-like cells and are primarily involved in produc-
tion of cytokines (96). NK cell activity is independent of 
antigen presentation and involves several inhibitory and 
activation receptors. The inhibitory receptors, e.g. KIR-
2DL or CD158/KIR3DL, bind to MHC class I molecules, 
the lack of which then triggers NK cell activation. How-
ever, for full NK cell activation, additional activating sig-
nals have to be present. The activation receptors, e.g CD16 
or NKG2D, bind ligands on tumour and virus-infected 
cells. CD16 is an Fcg receptor and binds to antibody 
coated targets, while NKG2D recognizes autologous lig-
ands that are upregulated by transformation, infection or 
cell stress (97). A single cell can express from two to four 
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inhibitory receptors and several activation receptors, then 
becoming activated only if activation signals outnumber 
the inhibitory signals (95). In addition, several cytokines, 
such as IL-2, IL-12, IL-15 and type I IFNs (IFN-a and 
IFN-b), can enhance the cytolytic, secretory, proliferative 
and anti-tumour NK cell functions (98, 99).
Apart from NK cells, other types of innate immune 
cell, monocytes and macrophages, can also destroy anti-
body coated targets via antibody-dependent cell cytotox-
icity; but the underlying mechanisms were unclear. How-
ever, it was recently shown that activation of Fcg receptor 
on monocytes triggers production of granzyme B and that 
granzyme B is responsible for a substantial portion of 
monocyte antibody-dependent cell cytotoxicity (100). 
Furthermore, activation of TLR8 also led to production 
of granzyme B and simultaneous activation of Fcg recep-
tor and TLR8 resulted in an additive effect. Moreover, 
treatment with TLR8 agonist also induced perforin and 
serpin B9 expression. These two reactions explain how 
monocytes can deliver granzyme B into the target cells 
and how they protect themselves, respectively (100).
CTLs on the other hand are the major component of 
the adaptive immune response. They develop from naive 
CD8+ T cells in the process of effector T cell differentia-
tion. Naive CD8+ T cells are small round cells that do 
not contain cytotoxic granules and circulate the periph-
ery. When they encounter the antigen presented by MHC 
class I molecules and in the presence of the appropriate 
co-stimulation on the surface of professional antigen pre-
senting cells, the T-cell receptor engagement triggers a 
cascade of intracellular events, ultimately leading to T cell 
activation. T cell activation leads to rapid clonal expan-
sion and effector differentiation and, in a few days, naive 
CD8+ cells differentiate into effector CTLs. CTLs are 
loaded with granzymes and perforin, in cytotoxic gran-
ules. Recognition of target cells by CTLs in the periphery 
leads to rapid polarized secretion of cytotoxic granules at 
the site of cell contact and triggers target cell apoptosis (3, 
101, 102).
REGULATION OF CELL CYTOTOXICITY 
BY CYSTATINS
Cystatins and cathepsins are involved in several pro-
cesses that regulate the cytotoxicity of NK cells and 
CTLs. In this regard their most important function is 
regulation of granzyme activation. (93). As noted above, 
the main cathepsin responsible for granzyme activation is 
cathepsin C but, at least for granzyme B, the alternative 
pro-granzyme convertase is cathepsin H. Furthermore, 
even cathepsin C and H null mice exhibit some residual 
granzyme B activity, suggesting another mechanism of 
activation (40).
The role of cystatins in regulation of cell cytotoxicity 
is less known. Cystatin C has been suggested as regulating 
cathepsin S activity and invariant chain (Ii) processing in 
dendritic cells (DCs), however, further studies excluded 
its role in controlling MHC II-dependent antigen presen-
tation in DCs. Cystatin SN has been found also in den-
dritic cells exposed to Toxoplasma gondii and it could 
thus modulate antigen presentation and consequently cell 
cytotoxicity of T cells (51). However, in cytotoxic cells the 
most prominent role in the regulation of cathepsin activ-
ity is attributed to cystatin F (Figure 1). Its preferential 
expression in immune cells and its endosomal/lysosomal 
localization already imply an important role in the im-
mune response (73, 76). In addition, cystatin F was found 
co-localized with granzyme A, perforin and Lamp-1 in 
human CD8+ T blasts, its overexpression in mouse CTLs 
led to decreased activity of cathepsin C (78). Another 
interesting feature of cystatin F is its ability to function 
in trans. It was shown that cystatin F null CTLs can take 
up cystatin F secreted by other CTLs. Furthermore, the 
internalized cystatin F was shown to attenuate cathepsin 
C activity directly (76). Localization of cystatin F in cy-
totoxic granules and its ability to regulate cathepsin C 
activity are strong advocates for its important role in the 
regulation of cytotoxicity of CTLs.
Expression of cystatin F is even higher in NK cells than 
in CTLs (74). In NK92 cell line cystatin F was found 
localized in lysosomes, co-localized with cathepsins C and 
H (104) (Figure 2). Like cystatin F in CTLs, in NK92 
cells as well as in primary human NK cells the mono-
meric form of cystatin F is N-terminally truncated (104), 
implying its inhibitory potential for cathepsin C and the 
regulation of cell cytotoxicity. In fact, it was shown by our 
group that higher levels of cystatin F in NK cells are as-
sociated with lower cytotoxicity and, concurrently, with 
the ability of NK cells to proliferate and secrete cytokines 
Figure 1. Schematic representation of the role of cystatin F and cys-
teine cathepsins in activation of effector molecules in cytotoxic cells. 
Cystatin F dimer is inactive as inhibitor of cysteine cathepsins. For 
monomerisation and activation it first needs to be proteolitically 
processed at the N-terminus, presumably by cathepsin V. Trun-
cated monomeric cystatin F becomes an inhibitor of cathepsins L, 
C and H and thus inhibits perforin processing and granzyme acti-
vation.
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(104). This cell status was termed split anergy by Jewett 
and colleagues to describe loss of NK cell cytotoxicity 
after their interaction with sensitive target cells (105). In-
teraction of NK cells with NK sensitive targets, such as 
tumour cells or monocytes, in some cases causes loss of 
cytotoxicity and triggers secretion of TNF-a and IFN-g, 
whereas their interaction with NK resistant targets does 
not (106). Split anergy involves down-modulation of 
CD16 receptor expression and can be induced by trigger-
ing CD16 with, for example, anti-CD16 antibodies in the 
presence or absence of IL-2. It was proposed that aner-
gized NK cells are important for tissue differentiation, 
regeneration and resolution of inflammation, while non-
anergized NK cells are important for stem cell selection 
(105). In anergized NK cells, levels of cathepsin C heavy 
chain were found to be lower than in IL-2 treated and 
non-treated NK cells, indicating decreased processing of 
pro-cathepsin C to mature cathepsin C after CD16 trig-
gering. Similarly, cathepsin H and granzyme B levels were 
also lower following CD16 triggering in the presence of 
IL-2 (104). On the other hand, the level of the cystatin F 
truncated monomeric form was significantly increased 
(104), potentiating inactivation of the convertase function 
of cathepsins C and H.
Increased levels of cystatin F could, in addition, con-
tribute to inhibition of other cathepsins such as cathepsin 
L and legumain. Interestingly, NK cells from legumain 
null mice display lower cytotoxicity, implying an impor-
tant role for legumain as well in cytotoxic cells (107). 
However, the mechanism underlying legumain involve-
ment in cytotoxicity is not known, though one possibility 
is through processing of either cathepsin L or H from their 
single chain to two chain forms (33). The fact that inter-
nalized exogenous cystatin F stabilizes cathepsin L protein 
levels and inhibits legumain in bone marrow-derived den-
dritic cells and macrophages supports this thesis (108).
CONCLUSIONS
Cysteine cathepsins and legumain are peptidases in-
volved in a variety of immune processes, among them 
activation of granule serine peptidases, a prerequisite step 
in the activation of cell cytotoxicity. Their function is 
regulated by the endogenous protein inhibitors cystatins. 
The most important of them is cystatin F that inhibits 
cathepsins C and H and consequently regulates the activa-
tion of granzymes. It can also regulate cytotoxic cell func-
tion through inhibition of cathepsin L and legumain and, 
in NK cells, cystatin F can promote split anergy, a type of 
NK cell response characterized by loss of cytotoxicity as-
sociated with failure of the anti-tumour immune response.
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